预约演示
更新于：2025-03-25
Sevelamer Hydrochloride
盐酸司维拉姆
更新于：2025-03-25
概要
基本信息
药物类型 聚合物 |
别名 Sevelamer hydrochloride (JAN/USAN)、GT16-026A、PB-94 + [4] |
作用方式 调节剂 |
作用机制 Phosphates 调节剂(磷酸盐 调节剂)、螯合剂 |
非在研适应症 |
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1998-10-30), |
最高研发阶段(中国)无进展 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C6H13Cl2NO |
InChIKeyKHNXRSIBRKBJDI-UHFFFAOYSA-N |
CAS号152751-57-0 |
关联
23
项与 盐酸司维拉姆 相关的临床试验NCT06660524
Clinical Study on the Influence of Calcium and Phosphorus Regulation Therapy on Valvular Heart Disease.
TCTR20230530004
Protein-bound uremic toxin lowering effects of sevelamer in end-stage kidney disease receiving hemodialysis with hyperphosphatemia: a randomized controlled trial
IRCT20200724048193N1
Comparing the Effect of Sevelamer Hydrochloride and Calcium Carbonate on Serum Level of hs-CRP, Soluable CD-14 and Endotoxin in Hemodialysis Patients
100 项与 盐酸司维拉姆 相关的临床结果
登录后查看更多信息
100 项与 盐酸司维拉姆 相关的转化医学
登录后查看更多信息
100 项与 盐酸司维拉姆 相关的专利（医药）
登录后查看更多信息
342
项与 盐酸司维拉姆 相关的文献（医药）2024-03-01Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis
Biochemical markers of iron status and iron accumulation in peritoneal dialysis patients treated with ferric citrate
Article
作者: Lea, Janice I ; Ajiboye, Oyintayo ; Navarrete, José E
Background::
Hyperphosphataemia is a common complication of kidney disease. Current dialysis techniques do not provide enough phosphorus clearance, hence the need to use phosphorus binders. Treatment options include calcium carbonate, calcium acetate, lanthanum carbonate, sevelamer hydrochloride and iron-based binders. Patients receiving peritoneal dialysis (PD) with sustained elevated ferritin levels exceeding 800 ng/mL are at a higher risk of death. We identify PD patients treated with iron-based binders and compare ferritin and risk of iron accumulation to patients treated with non-iron-based binders.
Methods::
All records of patients receiving PD at Emory dialysis centres until 30 October 2021 were reviewed for phosphorus binders. Basic demographics and laboratory data were time-referenced to the days on treatment with a particular binder. Patients were followed until discontinuation of the phosphorus binder, death, transplant, transfer to another dialysis provider or censoring at 36 months after medication was started.
Results::
Compared to calcium acetate and sevelamer, ferric citrate utilisation in PD patients resulted in a sustained increase in ferritin. The proportion of patients with a ferritin equal to or greater than 800 ng/dL and transferrin saturation greater than 40% increased over time in patients treated with ferric citrate and was higher during the second and third year of follow-up compared to baseline values and to patients treated with calcium acetate or sevelamer. Two patients (7%) treated with ferric citrate developed clinically significant haemosiderosis.
Conclusions::
Use of ferric citrated in PD resulted in significant iron accumulation as judged by ferritin levels.
2023-10-01Endocrinology, diabetes & metabolism case reports
Elderly-onset calcinosis of hyperphosphataemic familial tumoural calcinosis/hyperostosis-hyperphosphataemia syndrome: the role of comorbid scleroderma
Article
作者: Iwasaki, Hiroaki
Summary:
A 73-year-old woman with type 2 diabetes mellitus was referred to our department for glycaemic control. Physical examination revealed two subcutaneous hard masses around the left shoulder and the right hip joint. The patient could not fully extend her fingers because of skin sclerosis in both hands. Laboratory studies showed hyperphosphataemia and a high ratio of renal tubular maximum reabsorption of phosphate to glomerular filtration rate. There were no abnormalities in serum calcium, creatinine, alkaline phosphatase, and intact parathyroid hormone levels, whereas serum fibroblast growth factor 23 was low. Hyperphosphataemic familial tumoural calcinosis/hyperostosis-hyperphosphataemia syndrome (HFTC/HHS) was diagnosed using whole genome sequencing that revealed a novel frameshift beyond the 584th threonine located in the lectin domain of UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 3 associated with a duplication of the 1748th thymine in the coding region of the corresponding gene. Furthermore, anti-nuclear, anti-centromere, and anti-cardiolipin antibodies were positive, implying that comorbid limited type scleroderma might play a role in tumoural calcinosis (TC) development. A low phosphate diet was prescribed with phosphate-lowering medications, including aluminium hydroxide, acetazolamide, and sevelamer hydrochloride. The patient displayed a decrease in serum phosphate levels from 6.5 to 5.5 mg/dL 10 months after the initiation of treatment, but her TC had not improved during treatment for more than 1 year. This case was interesting because the patient with HFTC/HHS exhibited TC despite being over her 60s, and subsequent scleroderma might contribute to the specific clinical course. When HFTC/HHS presents with elderly-onset TC, the involvement of comorbidities in exacerbating TC should be considered.
Learning points:
HFTC/HHS occurs on an autosomal recessive basis, but its clinical course and manifestations differ significantly throughout the cases.HFTC/HHS may be undiagnosed until later in life because of its rarity, unfamiliarity, and phenotype diversity; therefore, HFTC/HHS should be included in the differential diagnosis of elderly patients with unexplained hyperphosphataemia or ectopic calcinosis.Comorbidities, including rheumatologic disorders, may contribute to developing HFTC/HHS-associated calcinosis.
2023-07-04Drug and chemical toxicology
In vitro cytogenetic analysis of two different anti-phosphates (sevelamer hydrochloride and calcium carbonate) agents used by patients with hyperphosphatemia
Article
作者: İla, Hasan Basri ; Ulaya, Goulzar
Sevelamer hydrochloride (SH) and calcium carbonate (CaCO3) are two agents included in the phosphate-binding group which are frequently prescribed in the treatment of patients with hyperphosphatemia. However, there are no satisfactory studies on the genotoxic effects of SH in vitro. This study was conducted to reveal the genotoxic and/or cytotoxic potential of these two drugs in cultured human peripheral lymphocytes. Human peripheral lymphocytes were treated with SH and CaCO3 at sublethal concentrations for 24 or 48 h for micronucleus assay and 1 h in the comet assay. CaCO3 and SH stimulated a slight increase in micronucleus formation however this increase was not significant compared to the control group. According to the findings of the comet test, only one concentration of the SH caused significant DNA damage (2 mg/ml, 48 h) whereas CaCO3 did not cause important DNA breakage. No significant oxidative damage or anti-radical effect caused by test substances was observed on the pure pBR322 plasmid DNA in a cell-free medium. Also, it was found that the drugs were devoid of mutagenic activity in the Ames test, but had a weak cytotoxic effect. Both test substances, particularly SH, significantly reduced the nuclear division index compared to the control group. In conclusion, the cytotoxic effect of SH was evident on the basis of in vitro tests and slightly higher than CaCO3.
100 项与 盐酸司维拉姆 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 慢性肾病-矿物质和骨骼疾病 | 欧盟 | 2015-02-25 | |
| 慢性肾病-矿物质和骨骼疾病 | 冰岛 | 2015-02-25 | |
| 慢性肾病-矿物质和骨骼疾病 | 列支敦士登 | 2015-02-25 | |
| 慢性肾病-矿物质和骨骼疾病 | 挪威 | 2015-02-25 | |
| 慢性肾病 | 澳大利亚 | 2005-06-30 | |
| 高磷血症 | 欧盟 | 2000-01-28 | |
| 高磷血症 | 冰岛 | 2000-01-28 | |
| 高磷血症 | 列支敦士登 | 2000-01-28 | |
| 高磷血症 | 挪威 | 2000-01-28 | |
| 终末期肾脏病 | 美国 | 1998-10-30 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 20 | Low Fat diet+Maltodextrin (Placebo) | 繭壓觸鹹蓋簾鬱築壓夢(獵壓簾艱餘憲醖壓齋鹹) = 憲膚選選願製願壓積鬱 鑰憲顧簾簾選衊範願廠 (鬱鬱顧鹹選膚鏇鑰積繭, 0) 更多 | - | 2021-10-15 | ||
Low Fat diet+Sevelamer (Sevelamer) | 繭壓觸鹹蓋簾鬱築壓夢(獵壓簾艱餘憲醖壓齋鹹) = 憲鏇顧鏇製艱選鏇衊簾 鑰憲顧簾簾選衊範願廠 (鬱鬱顧鹹選膚鏇鑰積繭, 2.4) 更多 | ||||||
临床2期 | 69 | NGT (Lean With NGT-Placebo) | 壓簾繭膚觸餘觸壓構齋(鹹憲窪廠選構醖蓋製鏇) = 簾淵願繭鑰積夢襯範壓 鏇醖鏇鑰顧艱鏇積簾鏇 (顧鹹遞積蓋艱廠襯構餘, 3.78) 更多 | - | 2020-09-11 | ||
(Lean With NGT-Sevelamer) | 壓簾繭膚觸餘觸壓構齋(鹹憲窪廠選構醖蓋製鏇) = 構繭鹹鹽蓋願網願窪鑰 鏇醖鏇鑰顧艱鏇積簾鏇 (顧鹹遞積蓋艱廠襯構餘, 2.25) 更多 | ||||||
临床3期 | 213 | PA21 (Sucroferric Oxyhydroxide) | 衊夢憲壓淵衊壓構憲積(觸壓觸夢網醖鏇鏇糧糧) = 衊積膚獵鹹衊憲繭鹹夢 憲鏇製鹽淵願網繭構醖 (鬱鑰淵糧齋鑰選積積憲 ) 更多 | 积极 | 2015-11-03 | ||
衊夢憲壓淵衊壓構憲積(觸壓觸夢網醖鏇鏇糧糧) = 醖遞網醖壓糧簾蓋簾選 憲鏇製鹽淵願網繭構醖 (鬱鑰淵糧齋鑰選積積憲 ) 更多 | |||||||
N/A | 111 | Sevelamer based PB | 獵艱蓋鬱糧憲遞選築網(襯膚簾廠淵製窪製積壓) = 繭蓋鹹顧鹹繭齋鏇繭鬱 鏇淵願顧觸壓製繭衊積 (鑰網憲鑰觸憲壓願鹽襯 ) 更多 | 积极 | 2015-05-21 | ||
Calcium based PB | 獵艱蓋鬱糧憲遞選築網(襯膚簾廠淵製窪製積壓) = 醖醖選齋顧餘膚窪願獵 鏇淵願顧觸壓製繭衊積 (鑰網憲鑰觸憲壓願鹽襯 ) 更多 | ||||||
N/A | 追加 | - | 遞簾觸選蓋襯顧鏇鬱簾(襯鏇齋鹽簾觸艱製遞膚) = 簾顧壓醖襯繭積選獵繭 鹽醖鏇齋糧鬱鹹鬱窪獵 (襯夢艱襯餘繭艱壓夢齋 ) | 积极 | 2014-05-01 | ||
No Sevelamer | 遞簾觸選蓋襯顧鏇鬱簾(襯鏇齋鹽簾觸艱製遞膚) = 淵築構鏇製積襯積鑰網 鹽醖鏇齋糧鬱鹹鬱窪獵 (襯夢艱襯餘繭艱壓夢齋 ) | ||||||
N/A | 高磷血症 维持 | 138 | 觸選鬱鏇顧夢顧衊鬱衊(築築觸願繭選膚鏇衊獵) = Gastrointestinal symptoms, of which most were mild or moderate, happened to 68.12% patients 遞獵願願獵網齋齋衊齋 (餘醖鹹範壓襯襯憲夢膚 ) | 积极 | 2011-11-08 | ||
临床3期 | 203 | 餘窪顧鹽選簾餘齋艱齋(遞範憲遞憲衊獵餘製窪) = more frequent with SBR759 鹹醖壓壓餘襯遞範蓋齋 (鏇壓憲齋廠鹽窪範築廠 ) 更多 | 积极 | 2010-11-16 | |||
Sevelamer-HCl | |||||||
临床2期 | 203 | 艱鬱醖鏇壓鹽範繭襯願(齋願艱鬱襯壓齋廠膚繭) = Similar incidences of SAE/AE were seen with SBR759 and S-HCl (5.2/90.3% vs 4.4/94.1%); no SAE was drug-related. Overall discontinuation rates were lower with SBR759 (11.9% vs 20.6%) as well as discontinuation due to AE (3.7% vs 13.2%). Most frequent AE category with SBR759 and S-HCl was gastrointestinal (GI) disorders (57.5% vs 64.7%). GI AE intensity was mostly mild with SBR759 (mild 45.5%, moderate 11.2%; severe 0.7%) whereas with S-HCl more moderate and severe AEs were reported (mild 30.9%; moderate 27.9%; severe 5.9%). Diarrhea AEs were more frequent with SBR759 (19.4% vs 10.3%); constipation and abdominal distension affected more patients on S-HCl (5.2% and 25.0% vs 3.0% and 25.0%, respectively). Based on Deficiency of Acquired Immune Deficiency Syndrome (DAIDS) grading, majority of diarrhea AE were of grade 1 (lowest severity) with SBR759 and S-HCl (18.7% vs 10.3%) 醖鹹糧齋糧廠範膚顧壓 (鑰遞網齋鏇願憲餘選蓋 ) | 积极 | 2010-11-16 | |||
N/A | 484 | Sevelamer Hydrochloride (SE) | 鹹製選繭築糧積願範夢(窪衊窪顧築廠遞顧鏇醖) = 齋構簾獵簾膚窪糧夢築 醖積製鬱壓蓋壓製醖簾 (選鹽構衊鏇廠繭顧網獵 ) 更多 | 积极 | 2010-11-16 | ||
(Non-SE) | 鹹製選繭築糧積願範夢(窪衊窪顧築廠遞顧鏇醖) = 簾鬱鏇獵範遞壓顧製蓋 醖積製鬱壓蓋壓製醖簾 (選鹽構衊鏇廠繭顧網獵 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用